A New Era for Ptosis Management

The Promise of a New Era in Demodex Blepharitis Treatment

This article discusses the newest investigational treatment for demodex blepharitis, TP-03 (lotilaner 0.25% ophthalmic solution; Tarsus Pharmaceuticals). Three optometrists dive into the treatment's importance, history and the results of completed clinical trials.

Supported by Tarsus Pharmaceuticals

A New Era for Ptosis Management

This article discusses how advanced eye drops are changing the paradigm of acquired ptosis care. In a conversation-based format, a group of optometrists talk about how to best manage ptosis patients in the changing times.

Sponsored by RVL Pharma

Additional Publications